Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BioMatrix
- Development stage
- Unknown
- Lead developer
- Biosensors International
- Modality
- Small Molecules
- Administration
- Implant
01
Overview
The BioMatrix drug-eluting stent (DES) is a coronary medical device developed by Biosensors International for the treatment of coronary artery disease and myocardial ischemia. It features a stainless steel stent platform coated with a biodegradable polylactic acid (PLA) polymer that elutes Biolimus A9 (umirolimus), a highly lipophilic analogue of sirolimus. The drug acts as an mTOR inhibitor, suppressing smooth muscle cell proliferation and neointimal hyperplasia to prevent restenosis following percutaneous coronary intervention (PCI). The BioMatrix stent is distinguished by its abluminal coating, which ensures drug delivery primarily to the vessel wall, and its biodegradable polymer, which fully resorbs into water and carbon dioxide within 6 to 9 months, potentially reducing long-term inflammation and the risk of very late stent thrombosis compared to permanent polymer stents.
- Brand names
- BioMatrixBioMatrix FlexBioMatrix AlphaBioMatrix Neo
- Other names
- Biomatrix drug eluting stentBiolimus A9-eluting stentBES
02
Targets
Mechanistic target of rapamycin complex 1FKBP1ARYR2 (Ryanodine receptor 2)
Beyond the preview
Go deeper on BioMatrix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioMatrix.